Managing patients with renal disease
|
|
- Logan Sherman
- 6 years ago
- Views:
Transcription
1 Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia
2 Prevalent cases, in millions, ± 95% CI Diabetic Kidney Disease is common 34% prevalence increase % prevalence increase All diabetic kidney disease Persistent albuminuria only (ACR 3 mg/g) Impaired egfr only (< 6 ml/min/1.73 m 2 ) Albuminuria and impaired egfr De Boer IH et al. JAMA 211;35:2532
3 Prevalence of kidney disease is projected to increase Estimated relative prevalence rate (per million population) Projection of CKD in patients with diabetes in 12 European countries* CKD Year CKD CKD Year CKD3, CKD stage 3; CKD4, CKD stage 4; CKD5, CKD stage 5 *Austria, Belgium, Denmark, Finland, Greece, Iceland, Italy, Netherlands, Norway, Spain, Sweden, UK Kainz A et al. Nephrol Dial Transplant 215;3:iv1113
4 Prevalence of ESRD around the world World Region Lynage Lancet 215
5 ESRD/Death (Event Rate, %) Despite RAAS blockade high residual risk for dialysis and mortality Early Intermediate Late Intervention BP Prot + GFR Conventional treatment RAAS intervention BP MA + 2 BP MA - BENEDICT ROADMAP IRMA-2 RENAAL IDNT ALL Cancers
6 New drugs for diabetic kidney disease Low Protein Diet (MDRD, no formal additive effect tested) NSAID s (proteinuria reduction, no hard endpoint trials) Combination ACEi/ARB (alb red, hard endpoints, NEPHRON; STOPPED) Renin-inhibitors (alb red, hard endpoints, ALTITUDE; CV/renal, STOPPED) Erythropoietin (Hb rise; hard endpoint trial; TREAT; CV/renal; NO EFFECT) GAG s(prot reduction; hard endpoint trial; SUN-Overt; renal; STOPPED) Statins (hard endpoint trial; SHARP;CV/renal; CV but NO RENAL EFFECT) Statins (prot reduction and GFR decline; PLANET trial; renal) Nrf2 agonist (rise in egfr; hard endpoint; BEACON; renal; STOPPED) Endothelin Antagonist (alb red; hard endpoint ; ASCEND; renal; STOPPED SONAR; ONGOING) SGLT2 inhibition (EMPAREG, CV benefit; CRENDENCE ongoing)
7 Day 1, ΔUGE -24h (g) Effects of SGLT2i on urinary glucose excretion depends on renal function GFR (ml/min/1.73m 2 ) egfr Normal Renal Function (n=3) 9 ml/min/1.73m 2 egfr Mild Renal Impairment (n=1) 6 to 89 ml/min/1.73m 2 egfr Moderate Renal Impairment (n=9) 3 to 59 ml/min/1.73m 2 egfr Severe Renal Impairment (n=1) 15 to 29 ml/min/1.73m 2 y = (r 2 adj:.783) 95% Confidence Band
8 Urinary glucose:creatinine ratio (mg/mg) Hba1c (%) change Effects of SGLT2i attenuates at lower egfr 45 to <6 ml/min/1.73m 6 6 to <9 ml/min/1.73m 2 9 ml/min/1.73m BL BL Study week Study week Heerspink et.al. ADA 216
9 Δ Hct (%) Effects of SGLT2i on volume related parameters independent of egfr Δ BW (Kg) Δ Systolic BP (mmhg) Δ UACR (%) Hematocrit Systolic BP BL Study week 45 to <6 ml/min 6 to <9 ml/min/ 9 ml/min/ 2 1 BL Study week -1 Body Weight 4 2 Albuminuria BL Study week BL Study week Heerspink et.al. ADA 216
10 3-point MACE: subgroup analysis by egfr Empagliflozin Placebo All patients Age, years.1 < Sex.81 Male Female Race.9 White Asian Black/African-American HbA1c, %.1 < Body mass index, kg/m 2.6 < egfr, ml/min/1.73m to < < Hazard ratio (95%CI) Zinman et.al. NEJM 215
11 EMPAREG CV death: subgroup analyses by egfr Empagliflozin Placebo All patients Age, years.21 < Sex.32 Male Female Race.43 White Asian Black/African-American HbA1c, %.51 < Body mass index, kg/m 2.5 < egfr, ml/min/1.73m to < < Zinman et.al. NEJM 215
12 Diabetes causes glomerular hypertension Na+/glucose cotransport SGLT2 SGLT2 SGLT2 Afferent arteriole Glomerular pressure GFR PT Efferent arteriole Glucose PT: Proximal tubule GL: Glomerulus MD: Macula densa Loop of Henle Renal hemodynamics under hyperglycemia Adapted from: Cherney D et al. Circulation 214;129:587
13 Empagliflozin lowers intra-glomerular pressure SGLT inhibitor blocks SGLT2 SGLT2 SGLT2 SGLT2 Afferent arteriole Glomerular pressure GFR PT Efferent arteriole Glucose PT: Proximal tubule GL: Glomerulus MD: Macula densa Loop of Henle Renal hemodynamics with empagliflozin Adapted from: Cherney D et al. Circulation 214;129:587
14 Tubular Na reabsorption in T1 diabetes mellitus Pollock CA et al (1991) Am. J. Physiol. 26: F946-F952
15 Fractional Sodium delivery diatal tuble (%) GFR (ml/min/1g Normalisation in GFR after phlorizin treatment in type 1 diabetes experimental model ,4 1,2 1,8,6,4,2 Control Diabetes D+Phlorizin Control Diabetes D+Phlorizin Pollock CA et al. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. (1991) Am. J. Physiol. 26: F946-F952
16 Mean intraglomerular pressure mmhg Empagliflozin reduces intra-glomerular pressure 8 7 ~6 8 mmhg Euglycemia * Hyperglycemia *p<.1 Baseline Empagliflozin Intra-glomerular pressure recorded at baseline and after 8 weeks treatment with empagliflozin Glomerular pressure T1D-H (mmhg) Baseline EMPA p value Change from baseline Euglycaemia (mmhg) 67.4 ± ± 5.2 <.1 9.5% Hyperglycaemia (mmhg) 69.3 ± ± 6.3 < % Skrtic M et al. Diabetologia 214;57:2599
17 Empagliflozin attenuates glomerular hyperfiltration Mean GFR (ml/min/1.73 m 2 ) Type 1 Diabetes: Glomerular filtration rate 172. * 139. GFR reduced by -33 ml/min/1.73 m 2 Baseline Empagliflozin *p<.1 T1D-H (Euglycemia) Type 1 diabetes patients with hyperfiltration. Mean GFR recorded at baseline and after 8 weeks treatment with empagliflozin 25 mg QD Cherney D et al. Circulation 214;129:587
18 Dapagliflozin causes a fall in mgfr in type 2 diabetes Mean GFR (ml/min/1.73m2) Mean GFR (ml/min/1.73m2) Type 2Diabetes: 12 Placebo 12 Dapagliflozin 1 1 GFR reduced by -1.1 ml/min/1.73m baseline week 12 6 baseline week 12 Heerspink et al. DOM 213
19 SGLT2i causes an acute fall in egfr followed by a complete stabilization Change in egfr (ml/min/1.73m 2 ) egfr slope (ml/min/1.73m 2 /year Glimepiride Canagliflozin 1 mg Canagliflozin 3 mg Glimepiride Cana 1 mg Cana 3 mg Time (weeks)
20 SGLT2i decreases risk of egfr decline endpoint Canagliflozin 1 mg vs glimepiride Overall population 3% egfr decline No. of events / patients Favors Favors Hazard Ratio Canagliflozin Glimepiride Canagliflozin Glimepiride (95% CI) p-value 3% egfr decline 32/477 46/475.66( ).7 4% egfr decline 7/477 11/475.61( ).3 UACR < 3 mg/g 25/43 29/4.83( ).51 UACR 3 mg/g 7/74 17/75.37(.15-.9) Hazard Ratio (95%CI)
21 Iothalamate GFR (ml/min) Blood pressure lowering with ACEi or β-blocker causes an acute and reversible fall in GFR Apperloo et.al. Kidney Int 1998
22 Long-term (3 years) egfr decline stratified by initial (3 months) egfr change Long-term egfr slope (ml/min/1.73m2/year) Tertiles of initial fall in egfr (-8.6) (-2.4) (+4.2) (-8.6) (-2.4) (+4.2) p=.9 Unadjusted analysis p=.49 Adjusted analysis Holtkamp et.al. Kidney Int 211
23 Renoprotection by reducing intraglomerular pressure SGLT2i tubuloglomerular feedback, afferent arteriole tone and intraglomerular pressure ACEi and ARB efferent arteriole tone and intraglomerular pressure Initial in egfr followed by stabilization albuminuria Initial in egfr followed by stabilization albuminuria Renal Protection (to be determined) Renal Protection Increased intraglomerular pressure and hyperfiltration are key steps in the progression of diabetic kidney disease
24 EMPAREG: Empagliflozin lowers risk of acute kidney injury Placebo Empa 1 Empa 25 Empa pooled Acute Kidney Injury 37 (1.6) 26 (1.1) 19 (.8) 45 (1.)* *P<.5 vs. placebo
25 Conclusions Effects of SGLT2i on glycemic control attenuate at lower renal function Effects on other CV risk factors are independent of GFR EMPAREG trial showed that effects of empagliflozin on CV outcomes are consistent regardless of egfr Restoration of TGF, reduction in intra-glomerular pressure, and albuminuria contribute to long-term renoprotective effects Future trials in patients with diabetic kidney disease (CREDENCE) will provide definitive answers on efficacy and safety in this population
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationSGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney?
SGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney? Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands Disclosures:
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationPaolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino
Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino The KID-ney behind the curtain Altered Renal Glucose Control in Diabetes Gluconeogenesis is increased in postprandial
More informationSGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective
SGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective Matthew R. Weir, MD Professor and Chief Division of Nephrology University of Maryland School of Medicine Disclosure Slide Scientific
More informationTreatment of diabetic kidney disease: landmark studies and tribulations
Division of Nephrology, Department of Medicine, The University of Hong Kong Treatment of diabetic kidney disease: landmark studies and tribulations Sydney C.W. TANG APSN/JSN Continuing Medical Education
More informationAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
original article http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 235 An acute fall in estimated glomerular filtration rate during treatment with losartan
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationThe albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients
Received: 5 February 217 Revised: 1 March 217 Accepted: 8 March 217 DOI: 1.1111/dom.12936 ORIGINAL ARTICLE The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationSodium Glucose Cotransporter-2 Inhibition and Renal Function
Sodium Glucose Cotransporter-2 Inhibition and Renal Function by Harindra Rajasekeran A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Physiology
More informationDiabetic Nephropathy Larry Lehrner, Ph.D.,M.D.
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationLECTURE 25: FILTRATION AND CLEARANCE NEPHRON FILTRATION
LECTURE 25: FILTRATION AND CLEARANCE NEPHRON FILTRATION 1. Everything in the plasma is filtered except large proteins and red blood cells. The filtrate in Bowman s capsule is an isosmotic fluid that is
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationDr Brandon Orr-Walker
Dr Brandon Orr-Walker Endocrinologist Clinical Head of Endocrinology and Diabetes Middlemore Auckland 17:45-18:10 What Can New Agents Offer Us? Diabetes Management What do the new agents offer us? Brandon
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationDiabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
More informationDapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin
University of Groningen Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin blockers Heerspink, H. J. L.; Johnsson, E.; Gause-Nilsson, I.; Cain, V. A.;
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationDiabetic Nephropathy
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationIntroduction to the kidney: regulation of sodium & glucose. Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health
Introduction to the kidney: regulation of sodium & glucose Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health Objectives Overview of kidney structure & function Glomerular
More informationEvaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationSGLT2 Inhibitors. Vijay Negalur
C H A P T E R 173 SGLT2 Inhibitors Vijay Negalur INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that results from insulin resistance, diminished
More informationCONGRESSO REGIONALE AMD - SID. Alleanza strategica nella gestione del paziente diabetico: attori a confronto Roma, 5-6 maggio 2017
CONGRESSO REGIONALE AMD - SID Alleanza strategica nella gestione del paziente diabetico: attori a confronto Roma, 5-6 maggio 2017 Il /la dr./sa Martina Vitale dichiara di NON aver ricevuto negli ultimi
More informationFor more information about how to cite these materials visit
Author(s): Frank Brosius, M.D, 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationRenal effects of canagliflozin in type 2 diabetes mellitus
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20 Renal effects of canagliflozin in type 2 diabetes mellitus Vlado
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationAvances en nefroprotección en la enfermedad renal diabética Cómo prevenir sus complicaciones y cómo tratarlas
Avances en nefroprotección en la enfermedad renal diabética Cómo prevenir sus complicaciones y cómo tratarlas Jesus Egido, MD, PhD Catedrático y Director, Departamento de Medicina. Universidad Autónoma
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationGeneral introduction of nephrology. Xiaoqiang Ding M.D., Ph.D. Department of nephrology Zhongshan Hospital, Fudan University
General introduction of nephrology Xiaoqiang Ding M.D., Ph.D. Department of nephrology Zhongshan Hospital, Fudan University Terminology Kidney,renal Nephrology Scope of nephrology Kidney diseases and
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationSGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar
SGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar David Balis, MD University of Texas Southwestern Medical Center Internal Medicine Grand Rounds 10/6/17 This is to acknowledge that
More informationToo much sodium is bad for you. Too much sodium is bad for you 13/09/2014. Salt- intake around the world. Sodium the most famous electrolyte
Sodium the most famous electrolyte Too much sodium is bad for you High blood pressure Cardiovascular disease Kidney damage Cerebrovascular hemorrhage Gerjan Navis Dept Nephrology, UMCG Groningen The Netherlands
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationPhysio 12 -Summer 02 - Renal Physiology - Page 1
Physiology 12 Kidney and Fluid regulation Guyton Ch 20, 21,22,23 Roles of the Kidney Regulation of body fluid osmolarity and electrolytes Regulation of acid-base balance (ph) Excretion of natural wastes
More informationMAJOR FUNCTIONS OF THE KIDNEY
MAJOR FUNCTIONS OF THE KIDNEY REGULATION OF BODY FLUID VOLUME REGULATION OF OSMOTIC BALANCE REGULATION OF ELECTROLYTE COMPOSITION REGULATION OF ACID-BASE BALANCE REGULATION OF BLOOD PRESSURE ERYTHROPOIESIS
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationBy: Dr. Foadoddini Department of Physiology & Pharmacology Birjand University of Medical Sciences. Body fluids and.
By: Dr. Foadoddini Department of Physiology & Pharmacology Birjand University of Medical Sciences Body fluids and Renal physiology 25 Volume and Osmolality of Extracellular and Intracellular Fluids
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationRenal safety of newer medications
Amar Puttanna MBChB, MRCP, Specialist Registrar, Department of Diabetes and Endocrinology, City Hospital, Birmingham, UK Lakshminarayanan Varadhan MBBS, MRCP (UK), MRCP Diabetes and Endocrinology, DipMedEd
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationChronic Kidney Disease DR. SANJAY PANDEYA MD. FRCPC.
Chronic Kidney Disease DR. SANJAY PANDEYA MD. FRCPC. Objectives Review CKD and its implications for the family physician Review the relevance of CKD and ESRD, its complications and management issues in
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationSGLT2 Inhibition in T2DM Management: Current Position and Future Promise
SGLT2 Inhibition, Diabetes and CVD: Where Does This Fit in CV Risk Management? ESC Congress, Rome, Italy 28 August, 2016 SGLT2 Inhibition in T2DM Management: Current Position and Future Promise Silvio
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More information